Calprotectin is a contributor to and potential therapeutic target for vascular calcification in chronic kidney disease

Archive ouverte

Amaya-Garrido, Ana | Brunet, Manon | Buffin-Meyer, Bénédicte | Piedrafita, Alexis | Grzesiak, Lucile | Agbegbo, Ezechiel | del Bello, Arnaud | Ferrandiz, Inés | Ardeleanu, Serban | Bermudez-Lopez, Marcelino | Fedou, Camille | Camus, Mylène | Burlet-Schiltz, Odile | Massines, Jean | Buléon, Marie | Feuillet, Guylène | Alves, Melinda | Neau, Eric | Casemayou, Audrey | Breuil, Benjamin | Saulnier-Blache, Jean-Sébastien | Denis, Colette | Voelkl, Jakob | Glorieux, Griet | Hobson, Sam | Arefin, Samsul | Rahman, Awahan | Kublickiene, Karolina | Stenvinkel, Peter | Bascands, Jean-Loup | Faguer, Stanislas | Valdivielso, José | Schanstra, Joost | Klein, Julie

Edité par CCSD ; American Association for the Advancement of Science (AAAS) -

International audience. Vascular calcification is an important risk factor for cardiovascular (CV) mortality in patients with chronic kidney disease (CKD). It is also a complex process involving osteochondrogenic differentiation of vascular smooth muscle cells (VSMCs) and abnormal deposition of minerals in the vascular wall. In an observational, multicenter European study, including 112 patients with CKD from Spain and 171 patients on dialysis from France, we used serum proteome analysis and further validation by ELISA to identify calprotectin, a circulating damage-associated molecular pattern protein, as being independently associated with CV outcome and mortality. This was confirmed in an additional cohort of 170 patients with CKD from Sweden, where increased serum calprotectin concentrations correlated with increased vascular calcification. In primary human VSMCs and mouse aortic rings, calprotectin exacerbated calcification. Treatment with paquinimod, a calprotectin inhibitor, as well as pharmacological inhibition of the receptor for advanced glycation end products and Toll-like receptor 4 inhibited the procalcifying effect of calprotectin. Paquinimod also ameliorated calcification induced by the sera of uremic patients in primary human VSMCs. Treatment with paquinimod prevented vascular calcification in mice with chronic renal failure induced by subtotal nephrectomy and in aged apolipoprotein E–deficient mice as well. These observations identified calprotectin as a key contributor of vascular calcification, and increased circulating calprotectin was strongly and independently associated with calcification, CV outcome, and mortality in patients with CKD. Inhibition of calprotectin might therefore be a promising strategy to prevent vascular calcification in patients with CKD.

Consulter en ligne

Suggestions

Du même auteur

A universal predictive and mechanistic urinary peptide signature in acute kidney injury

Archive ouverte | Piedrafita, Alexis | CCSD

International audience. Background The delayed diagnosis of acute kidney injury (AKI) episodes and the lack of specificity of current single AKI biomarkers hamper its management. Urinary peptidome analysis may help ...

CALPROTECTIN IS A NOVEL CONTRIBUTING FACTOR IN VASCULAR CALCIFICATION AND A PREDICTOR OF CARDIOVASCULAR OUTCOME IN CKD PATIENTS

Archive ouverte | Amaya-Garrido, Ana | CCSD

International audience. Background and AimsVascular calcification, leading to aortic stiffening and heart failure, is decisive risk factor for cardiovascular (CV) mortality in patients with chronic kidney disease (C...

Mapping of the amniotic fluid proteome of fetuses with congenital anomalies of the kidney and urinary tract identifies plastin 3 as a protein involved in glomerular integrity

Archive ouverte | Fédou, Camille | CCSD

International audience. Congenital anomalies of the kidney and the urinary tract (CAKUT) are the first cause of chronic kidney disease in childhood. Several genetic and environmental origins are associated with CAKU...

Chargement des enrichissements...